Outstanding Q1 growth in sales and profits have pleased the markets, and investors are now keen to hear more about AstraZeneca’s 2030 masterplan at its investor day next month.

Guest Andrew McConaghie from Scrip's UK team joins Brian Yang and Dexter Yan to discuss AACR highlights from Chinese biotechs, European perspectives on the proposed US BIOSECURE Act, two recent acquisitions and Boehringer Ingelheim's recent quarterly results.

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.